Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study ...
FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...
You do not need fingers to notice more versus less. Across forests, oceans, and backyards, animals make split second choices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback